Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Dow
Merck
QuintilesIMS
Fish and Richardson
Argus Health
UBS
Medtronic
Julphar

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,846,961

« Back to Dashboard

Which drugs does patent 7,846,961 protect, and when does it expire?

Patent 7,846,961 protects PRESTALIA and is included in one NDA.

This patent has twenty-six patent family members in twenty-six countries.
Summary for Patent: 7,846,961
Title:.alpha. crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
Abstract: .alpha.-crystalline form of the compound of formula (I): ##STR00001## characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
Inventor(s): Coquerel; Gerard (Boos, FR), Lefebvre; Loic (Mont Saint Aignan, FR), Souvie; Jean-Claude (Pau, FR), Authouart; Pascale (Les Trois Pierres, FR)
Assignee: Les Laboratoires Servier (Suresnes Cedex, FR)
Application Number:12/224,369
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,846,961

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Marina Biotech PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-001 Jan 21, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF HYPERTENSION ➤ Try a Free Trial
Marina Biotech PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-002 Jan 21, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF HYPERTENSION ➤ Try a Free Trial
Marina Biotech PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-003 Jan 21, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF HYPERTENSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,846,961

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 01748Feb 28, 2006
PCT Information
PCT FiledFebruary 26, 2007PCT Application Number:PCT/FR2007/000335
PCT Publication Date:September 07, 2007PCT Publication Number: WO2007/099217

International Patents Family Members for US Patent 7,846,961

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007220435 ➤ Try a Free Trial
Brazil PI0708278 ➤ Try a Free Trial
Canada 2644467 ➤ Try a Free Trial
China 101389603 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Julphar
Johnson and Johnson
US Department of Justice
QuintilesIMS
Mallinckrodt
McKesson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.